Kris Cameron Wood
Assistant Professor of Pharmacology & Cancer Biology
Appointments and Affiliations
- Assistant Professor of Pharmacology & Cancer Biology
- Assistant Professor of Biomedical Engineering
- Member of the Duke Cancer Institute
Contact Information
- Email Address: kris.wood@duke.edu
- Websites:
Education
- Ph.D. Massachusetts Institute of Technology, 2007
- B.S. University of Kentucky at Lexington, 2002
Research Interests
More effective anticancer therapeutic strategies, many of which are based on functional genomics. Examples of projects include: a miniaturized screening platform, tools to systematically map the signaling pathways controlling anticancer drug responses, high-throughput computational methods to discover anticancer drug combinations, design of therapeutic strategies to reverse or prevent drug resistance, and systematic credentialing of mutations uncovered through cancer genome sequencing projects.
Courses Taught
- MOLCAN 780: Graduate Student Seminar
- MOLCAN 818: Molecular Mechanisms of Oncogenesis
- PHARM 393: Research Independent Study
- PHARM 394: Research Independent Study
- PHARM 493: Research Independent Study
- PHARM 494: Research Independent Study
- PHARM 780S: Graduate Student Seminar
- PHARM 818: Molecular Mechanisms of Oncogenesis
In the News
- The Challenges of Combating Cancer Drug Resistance (Nov 19, 2015 | Duke Research Blog )
- Researchers Map Paths to Cancer Drug Resistance (Jan 5, 2015)
Representative Publications
- Price, AM; Dai, J; Bazot, Q; Patel, L; Nikitin, PA; Djavadian, R; Winter, PS; Salinas, CA; Barry, AP; Wood, KC; Johannsen, EC; Letai, A; Allday, MJ; Luftig, MA, Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection., eLife, vol 6 (2017) [10.7554/elife.22509] [abs].
- Wood, KC, Suppressing oncogenic transcription with a little healthy competition., Science Translational Medicine, vol 9 no. 374 (2017) [10.1126/scitranslmed.aal5000] [abs].
- Wood, KC, An EXITS strategy for decreasing cancer risk in women., Science Translational Medicine, vol 8 no. 368 (2016) [10.1126/scitranslmed.aal2806] [abs].
- Anderson, GR; Wardell, SE; Cakir, M; Crawford, L; Leeds, JC; Nussbaum, DP; Shankar, PS; Soderquist, RS; Stein, EM; Tingley, JP; Winter, PS; Zieser-Misenheimer, EK; Alley, HM; Yllanes, A; Haney, V; Blackwell, KL; McCall, SJ; McDonnell, DP; Wood, KC, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Science Translational Medicine, vol 8 no. 369 (2016) [10.1126/scitranslmed.aae0348] [abs].
- Wood, KC, Hacking T cells with synthetic circuits to program antitumor responses, Science Translational Medicine, vol 8 no. 362 (2016), pp. 362ec172-362ec172 [10.1126/scitranslmed.aai9170] [abs].